+14.1%
GSK vs SOLS
+20.3%
-6.2%
-18.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | SOLS | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.2% | -2.0% | +2.2% | +0.2% |
| 7D | -3.6% | +3.7% | -7.3% | -3.6% |
| 30D | -5.9% | +5.0% | -10.9% | -5.9% |
| 3M | -4.3% | -21.1% | +16.8% | -4.0% |
| 6M | -10.8% | -14.2% | +3.4% | -10.8% |
| YTD | +1.8% | +30.6% | -28.8% | +4.2% |
| All | +14.1% | +20.3% | -6.2% | +17.2% |
Cumulative growth
Daily Returns
Daily percentage return beside SOLS.
Daily Out/Under-Performance
Portfolio return minus SOLS return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × SOLS return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded SOLS wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling